Showing results (1741-1750 of 1,873) with videos related to

Sort By:
Pageof 188
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
European Journal of Heart Failure|September 10, 2023
Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF modelPascal M Burger, Gianluigi Savarese, Jasper Tromp, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
The New England Journal of Medicine|November 6, 2012
Strategies for multivessel revascularization in patients with diabetesMichael E Farkouh, Michael Domanski, Lynn A Sleeper, et al.
JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 188